title: Bupropion sustained release for bereavement: results of an open trial.
abstract: OBJECTIVE
  The present study was conducted to assess whether DSM-IV-defined bereavement responds to bupropion sustained release (SR).
  
  
  METHODS
  Twenty-two subjects who had lost their spouses within the previous 6 to 8 weeks and who met DSM-IV symptomatic/functional criteria for a major depressive episode were evaluated. Subjects completed the Hamilton Rating Scale for Depression (HAM-D), the Clinical Global Impressions scale, the Texas Revised Inventory of Grief, and the Inventory of Complicated Grief at baseline and follow-up. Subjects were treated with bupropion SR, 150 to 300 mg/day, for 8 weeks.
  
  
  RESULTS
  Improvement was noted in both depression and grief intensity. For the intent-to-treat group. 59% experienced a reduction of > or = 50% on HAM-D scores. The correlations between changes in the HAM-D scores and the grief scale scores were high, ranging from 0.61 (p = .006) to 0.44 (p = .054).
  
  
  CONCLUSIONS
  Major depressive symptoms occurring shortly after the loss of a loved one (i.e., bereavement) appear to respond to bupropion SR. Treatment of these symptoms does not intensify grief; rather, improvement in depression is associated with decreases in grief intensity. The results of this study challenge prevailing clinical wisdom that DSM-IV-defined bereavement should not be treated. Larger, placebo-controlled studies are indicated.
authors.affiliation: Department of Psychiatry, University of California San Diego, La Jolla 92093, USA. szistook@ucsd.edu.
authors.forename: S
authors.initials: S
authors.lastname: Zisook
authors.forename: S R
authors.initials: SR
authors.lastname: Shuchter
authors.forename: P
authors.initials: P
authors.lastname: Pedrelli
authors.forename: J
authors.initials: J
authors.lastname: Sable
authors.forename: S C
authors.initials: SC
authors.lastname: Deaciuc
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use*; D001601:Bereavement; D016642:Bupropion / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory / Q000706:statistics & numerical data; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D016896:Treatment Outcome; D017805:Widowhood / Q000523:psychology
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D016642:Bupropion